<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624580</url>
  </required_header>
  <id_info>
    <org_study_id>NN6582-4838</org_study_id>
    <secondary_id>U1111-1274-4316</secondary_id>
    <secondary_id>2022-001813-38</secondary_id>
    <nct_id>NCT05624580</nct_id>
  </id_info>
  <brief_title>A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults</brief_title>
  <official_title>Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injections of NNC0582-0001 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, sequential-group, placebo-controlled study&#xD;
      with six sequential single dose cohorts with ascending dose levels in healthy adult&#xD;
      participants. This study will assess the safety, tolerability, the pharmacokinetics from&#xD;
      single subcutaneous administrations of NNC0582-0001 and explores the pharmacodynamics in&#xD;
      healthy participants. Participants will be randomized in a 3:1 ratio to receive a fixed&#xD;
      single dose (1-day) of NNC0582 0001 or placebo by injections under the skin. Participants&#xD;
      will be followed up for 52 weeks post dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2022</start_date>
  <completion_date type="Anticipated">June 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From dosing (Day 1) until End of Study visit (Week 52)</time_frame>
    <description>Measured as number of events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-âˆž: The area under the NNC0582-0001 plasma concentration-time curve from time zero to infinity after a single dose.</measure>
    <time_frame>From dosing (Day 1) to 168 hours after dosing</time_frame>
    <description>Measured in nanomole hour per liter (nmol*h/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: The maximum concentration of NNC0582-0001 in plasma</measure>
    <time_frame>From dosing (Day 1) to 168 hours after dosing</time_frame>
    <description>Measured in nanomole per liter (nmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax: The time from dose administration to maximum plasma concentration of NNC0582-0001</measure>
    <time_frame>From dosing (Day 1) to 168 hours after dosing</time_frame>
    <description>Measured in days.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single Dose 1: NNC0582-0001 10 milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of NNC0582-0001 10 mg or matching placebo injection subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose 2: NNC0582-0001 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of NNC0582-0001 30 mg or matching placebo injection subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose 3: NNC0582-0001 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of NNC0582-0001 90 mg or matching placebo injection subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose 4: NNC0582-0001 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of NNC0582-0001 250 mg or matching placebo injection subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose 5: NNC0582-0001 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of NNC0582-0001 600 mg or matching placebo injection subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose 6: NNC0582-0001 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of NNC0582-0001 1000 mg or matching placebo injection subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0582-0001</intervention_name>
    <description>Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.</description>
    <arm_group_label>Single Dose 1: NNC0582-0001 10 milligram (mg)</arm_group_label>
    <arm_group_label>Single Dose 2: NNC0582-0001 30 mg</arm_group_label>
    <arm_group_label>Single Dose 3: NNC0582-0001 90 mg</arm_group_label>
    <arm_group_label>Single Dose 4: NNC0582-0001 250 mg</arm_group_label>
    <arm_group_label>Single Dose 5: NNC0582-0001 600 mg</arm_group_label>
    <arm_group_label>Single Dose 6: NNC0582-0001 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.</description>
    <arm_group_label>Single Dose 1: NNC0582-0001 10 milligram (mg)</arm_group_label>
    <arm_group_label>Single Dose 2: NNC0582-0001 30 mg</arm_group_label>
    <arm_group_label>Single Dose 3: NNC0582-0001 90 mg</arm_group_label>
    <arm_group_label>Single Dose 4: NNC0582-0001 250 mg</arm_group_label>
    <arm_group_label>Single Dose 5: NNC0582-0001 600 mg</arm_group_label>
    <arm_group_label>Single Dose 6: NNC0582-0001 1000 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female of non-childbearing potential or male aged 18-55 years (both inclusive) at the&#xD;
             time of signing informed consent.&#xD;
&#xD;
          -  Body Mass Index (BMI) from 20.0 to 30.0 kilogram per square meter (kg/m^2) (both&#xD;
             inclusive) at screening.&#xD;
&#xD;
          -  Considered to be generally healthy based on the medical history, physical examination,&#xD;
             and the results of vital signs, electrocardiogram, and clinical laboratory tests&#xD;
             performed during the screening visit, as judged by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disorder, which in the investigator's opinion might jeopardise participant's&#xD;
             safety or compliance with the protocol.&#xD;
&#xD;
          -  Glycated haemoglobin (HbA1c) greater than or equal to 5.7 percent (48 millimoles per&#xD;
             mole [mmol/mol]) at screening.&#xD;
&#xD;
          -  Any of the below laboratory safety parameters at screening outside normal range, see&#xD;
             laboratory provided reference ranges for specific values (re-screening or re-sampling&#xD;
             is NOT allowed if the participant has failed one of the exclusion criteria related to&#xD;
             laboratory parameters):&#xD;
&#xD;
          -  Alanine aminotransferase (ALT)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)&#xD;
&#xD;
          -  Bilirubin&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) below 90 milliliters per kilogram per&#xD;
             minute (mL/kg/min).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency dept. 2834</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

